9n1w8gzgrqq3iltmyams axio

Axiogenesis

Cologne North Rhine-Westphalia

Axiogenesis is an international leader in the development and commercialization of in vitro models of healthy and diseased cell types and tissue. Axiogenesis' technologies greatly improve the speed and confidence in discovering new therapies, and reduce attrition of failed compounds.

Since 2000, Axiogenesis has been in business to capture the promise of stem cells to revolutionize the fields of drug discovery & development and life sciences research. Axiogenesis develops and commercializes stem cell-derived, in vitro differentiated cardiomyocytes, neurons and other cell types, as well as drug development assays and disease models, to help researchers discover cures.

Axiogenesis' flagship offering is the Cor.4U® human cardiomyocyte product, derived from induced pluripotent stem (iPS) cells, which is used in applications for single cell analysis to high-throughput screening (HTS) of pharmaceutical... Show more »

Axiogenesis is an international leader in the development and commercialization of in vitro models of healthy and diseased cell types and tissue. Axiogenesis' technologies greatly improve the speed and confidence in discovering new therapies, and reduce attrition of failed compounds.

Since 2000, Axiogenesis has been in business to capture the promise of stem cells to revolutionize the fields of drug discovery & development and life sciences research. Axiogenesis develops and commercializes stem cell-derived, in vitro differentiated cardiomyocytes, neurons and other cell types, as well as drug development assays and disease models, to help researchers discover cures.

Axiogenesis' flagship offering is the Cor.4U® human cardiomyocyte product, derived from induced pluripotent stem (iPS) cells, which is used in applications for single cell analysis to high-throughput screening (HTS) of pharmaceutical compounds. Cor.4U® cardiomyocytes: Pure. Human.™ Axiogenesis was first-to-market with a pure stem cell-derived cardiomyocyte product, launching Cor.At® murine cardiomyocytes in 2008. Cor.At® cardiomyocytes, along with murine stem cell-derived endothelial cells (Endo.4M) and smooth muscle cells (SMAC.4M), are distributed globally by Sigma Life Sciences.

Axiogenesis' innovative and proprietary cell types and assays accelerate and improve drug candidate selection, lower costs and thus increase overall drug development efficiency.

Selected Publications

  • Franz D, Olsen HL, Klink O, Gimsa J. Automated and manual patch clamp data of human induced pluripotent stem cell-derived dopaminergic neurons. Sci Data. 2017 Apr 25;4:170056. doi: 10.1038/sdata.2017.56.
  • Zhao L, Zhang B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci Rep. 2017 Mar 16;7:44735. doi: 10.1038/srep44735.
  • Blinova K, Stohlman J, Vicente J, Chan D, Johannesen L, Hortigon-Vinagre MP, Zamora V, Smith G, Crumb WJ, Pang L, Lyn-Cook B, Ross J, Brock M, Chvatal S, Millard D, Galeotti L, Stockbridge N, Strauss DG. Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias. Toxicol Sci. 2017 Jan;155(1):234-247. doi: 10.1093/toxsci/kfw200.
  • Goßmann M, Frotscher R, Linder P, Neumann S, Bayer R, Epple M, Staat M, Artmann AT, Artmann GM. Mechano-Pharmacological Characterization of Cardiomyocytes Derived from Human Induced Pluripotent Stem Cells. Cell Physiol Biochem. 2016;38(3):1182-98. doi: 10.1159/000443124.
  • Frotscher R, Muanghong D, Dursun G, Goßmann M, Temiz-Artmann A, Staat M. Sample-specific adaption of an improved electro-mechanical model of in vitro cardiac tissue. J Biomech. 2016 Aug 16;49(12):2428-35. doi: 10.1016/j.jbiomech.2016.01.039.
  • Becker N, Stoelzle S, Göpel S, Guinot D, Mumm P, Haarmann C, Malan D, Bohlen H, Kossolov E, Kettenhofen R, George M, Fertig N, Brüggemann A. Minimized cell usage for stem cell-derived and primary cells on an automated patch clamp system. J Pharmacol Toxicol Methods. 2013 Jul-Aug;68(1):82-7. doi: 10.1016/j.vascn.2013.03.009.
  • Abassi YA, Xi B, Li N, Ouyang W, Seiler A, Watzele M, Kettenhofen R, Bohlen H, Ehlich A, Kolossov E, Wang X, Xu X. Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment. Br J Pharmacol. 2012 Mar;165(5):1424-41. doi: 10.1111/j.1476-5381.2011.01623.x.
« Show less

Axiogenesis has not listed any services.

In vitro Cardiotoxicity Screening
Price on request

CardioFlux - Cor.4U calcium transient analysis

CardioFlux utilizes intracellular calcium transients and beat rate analysis of Cor.4U® human induced pluripotent stem (iPS) cell-derived cardiomyocytes to assess cardiac liability and efficacy of drug compounds.

Transient rise of cytosolic free calcium ion concentrations... Show more »

CardioFlux - Cor.4U calcium transient analysis

CardioFlux utilizes intracellular calcium transients and beat rate analysis of Cor.4U® human induced pluripotent stem (iPS) cell-derived cardiomyocytes to assess cardiac liability and efficacy of drug compounds.

Transient rise of cytosolic free calcium ion concentrations ([Ca2+ ]i ) plays a pivotal role in cardiomyocyte contraction. During the cardiac action potential, the rise and duration of these calcium transients [Ca2+ ]i are carefully controlled by a mechanism called the calcium-induced calcium release.

Direct acute drug effects, including interference with ion channels, pumps, exchangers and hormone receptors, or kinase-mediated signaling involved in regulation of the human cardiomyocyte action potential and heart rate control can be detected by monitoring [Ca2+ ]i transients, which makes it a valuable tool in drug discovery and safety pharmacology assessment.

In the ongoing CiPA validation study, calcium transient measurements are one of three methods to assess pro-arrhythmic effects on a subset of blinded compounds in Cor.4U® cardiomyocytes.
The CardioFlux assay has been validated with >75 compounds from a wide variety of compound classes.

**Cells
-Cor.4U® / vCor.4U® cardiomyocytes or co-cultures of cardiomyocytes with FibroCor.4U cardiac fibroblasts
*
Cell source
-Human iPS cells of 26y/o Caucasian female
*
Service Type
-Functional / phenotypic analysis
*
Delivery
- A study protocol will be sent to initiate the study. Results are sent as draft and final study report
*
*Timeline
-Experimental run time: ~1.5 weeks per plate, Draft report: within 5 weeks.

ADVANTAGES

-Cost-effective, robust and fast assay to assess toxicity/efficacy early in drug development
-Combines Cor.4U® , a well-characterized predictive cardiac model, with HTS capabilities
-Highly validated assay; part of the CiPA (Comprehensive in Vitro Proarrhythmia Assay) initiative

CardioEffect - Cor.4U impedance analysis

CardioEffect combines Cor.4U® human cardiomyocytes with impedance technology (xCELLigence RTCA Cardio, ACEA Biosystems) to provide a homogenous and standardized assay system for in vitro detection of compound effects on cell beating. This includes changes of spike amplitude, beating frequency, induction of arrhythmia, and beating arrest.

CardioEffect has been validated in house using 24 drugs with known cardiac safety profiles. Through years of service, Axiogenesis has experience with hundreds of compounds from a variety of classes and indications. Reference compounds are included on each assay plate for quality assurance. In addition to phenotypic assessment of contractile motion, this assay provides a surrogate measure of cytotoxicity via the “Cell Index”.

CardioEffect provides an ideal tool to assess cardiomyocyte function, safety pharmacology / toxicity effects of drug candidates, etc. on human cardiac myocytes in a label-free, real time assay. Understanding cardiotoxic liabilities of compounds in early stages of drug development establishes confidence to move lead compounds towards pre-clinical and clinical development.

**Cells
-Cor.4U® human iPS-derived cardiomyocytes
*
Species
-Human iPS cells of 26y/o Caucasian female
*
Service Type
-functional / phenotypic analysis
*
Delivery
-A study protocol will be sent to initiate the study. Results are sent as draft and final study report.
*
*Timeline
-Experiment run time: 1 week per plate, Draft report: within 4 weeks

ADVANTAGES

-Predictive, relevant and robust 96-well assay system based on integrated cell culture model representing primary-like cardiac physiology
-Analysis of both acute and long-term effects on cardiomyocyte beating and overall cell health; combination with other read-outs of cell viability and cytotoxicity possible
-Time- and cost effective assessment of compound safety accelerating lead selection

Mel.Cor - Cor.4U MEA Assay Service

Human Cor.4U® Mel.Cor® is an in vitro and non-invasive assay system to monitor Axiogenesis' Cor.4U® human induced pluripotent stem (iPS) cell-derived cardiomyocytes by means of extracellular field potential recordings from microelectrode arrays (MEA).

The Cor.4U® human iPS cell-derived cardiomyocytes reveal electrophysiological properties typical for human cardiac myocytes like functional Na+, Ca2+, and K+ voltage-gated ion channels including the hERG channel and their correct modulation through e.g. ß-adrenergic or muscarinic receptors.

The combination of the Cor.4U® human cardiomycoytes with the Mel.Cor® MEA assay provides an ideal tool to assess pharmacological, safety pharmacological and toxicological effects of drug candidates on human cardiomyocytes.

**Cells
-Cor.4U® Human iPS derived cardiomyocytes
*
Species
-Human
*
Cell Source
-Human iPS cells of 26y/o Caucasian female
*
Cell Format
-Monolayer of pure cardiomyocytes
*
Service type
-Functional / phenotypic analysis
*
Delivery
-A study protocol will be sent to initiate the study. Results are sent as draft and final study report
*
*Timeline
-Experimental run time: ~1.5 weeks per plate. Draft report: within 4 weeks.

ADVANTAGES

-Primary-like electrophysiology from cardiomyocytes of human origin
-Non-invasive / label-free test system up to 96-well format
-Predictive and relevant for cardiac safety pharmacology
-Time- and cost-effective; Low amount of compound required

Cardio.Force - Cardiac contractile force assay

The CardioForce cardiac cell contractile force assay is based on the proprietary Cor.4CE® system developed by Axiogenesis, a non-invasive in vitro assay to measure true contractility of cardiomyocyte monolayers or co-cultures of cardiomyocytes with cardiac fibroblasts. Cor.4U® human iPSC-derived cardiomyocytes reveal mechanical properties typical for human cardiac myocytes (Goßmann et al, 2016). The Cor.4CE® system allows for repeatable contractility measurements with unprecedented accuracy under physiological mechanical boundary conditions. In contrast to surrogate technologies like impedance sensing, the Cor.4CE® system shows the expected physiological force-frequency-relationships for adrenergic stimulation.

The combination of Cor.4U with the Cor.4CE® system is the first in vitro assay setup to measure true contractile force of iPSC-derived cardiomyocytes in a system compatible with medium throughput. The system provides an ideal tool to assess pharmacological, safety pharmacological and toxicological effects of drug candidates on human cardiomyocytes.

**Cell Type
-Cor.4U human iPSC-derived cardiomyocytes or co-cultures with FibroCor.4U human iPSC-derived cardiac fibroblasts
*
Cell Source
-Human iPSC of 26 y/o Caucasian female
*
Service Type
-Biomechanical analysis
*
Delivery
-A study protocol will be sent to initiate the study
*
*Timeline
-Draft report will be sent within 7 weeks after receipt of test compounds

ADVANTAGES

-True force measurement in human iPSC derived cardiomyocytes using proprietary Cor.4CE® assay technology
-Highly precise, standardized and repeatable test system
-Sensitive and predictive for cardiac safety pharmacology
-Suitable for scale-up given low compound volumes, quick turnaround

« Show less
Human
Imaging
Cardiovascular
Cardio
Drug discovery
Transient expression
cardiovascular
hERG
Nav1.5
Cardiomyopathy
cardiometabolism
Cardiac Function
Ion Channel
arrhythmia
arrhythmia
cardiomyopathy
cardiotoxicity
cardiac safety
Axion Maestro
MEA
MEA
Axion Maestro
cardiotoxicity
cardiac safety
XCELLigence
Impedance
ACEA XCELLigence
drug toxicity
Hamamatsu
Hamamatsu FDSS
Calcium imaging
calcium imaging
calcium dye
calcium transient
Hamamatsu FDSS
Hamamatsu
calcium dye
transient transfection
Xpress.4U
GCAMP6
calcium efflux
calcium
Nanion CardioExcyte
Microelectrode Array
CardioExcyte
ACEA
Nanion
ChR2
Channel Rhodopsin
Lipidsome
mRNA
In vitro Embryotoxicity & Teratogenicity Screening
Price on request

µEST - In vitro Embryotoxicity Screening

The µEST@ test system utilises the ability of mouse embryonic stem cells (ES cells) to differentiate in vitro into various tissues of all three germ layers. Supposing that exposure of ES cells to embryotoxic and teratogenic compounds during this process interferes with correct... Show more »

µEST - In vitro Embryotoxicity Screening

The µEST@ test system utilises the ability of mouse embryonic stem cells (ES cells) to differentiate in vitro into various tissues of all three germ layers. Supposing that exposure of ES cells to embryotoxic and teratogenic compounds during this process interferes with correct differentiation, the resulting amount of a given tissue, e.g. cardiac tissue, will be a marker for developmental toxicity. To distinguish a specific embryotoxic effect from a plain cytotoxic effect, results of the µEST@ are compared to results from a standard cytotoxicity assay (XTT test).

The mechanistic principle of the test was described by Spielmann et al. in 1997 and validated by the ECVAM Scientific Advisory Committee (ESAC) in 2001. The µEST@ test system was stated equivalent to the validated EST by ECVAM, and gained acceptance as "suitable for REACH" by ECVAM in 2008.

Predictivity of µEST@ (70 compounds tested within the ECVAM validation studies):

Specificity 87%
Sensitivity 88%
Negative predictive value 81%
Positive predictive value 91%
Accuracy 87%

**Cells
-Embryonic stem cells bearing a read-out system for cardiac differentiation
*
Species
-Mouse
*
Reporter
-TAQ GFP or SEAP
*
Service Content
-Comparative investigation of embryotoxicity and/or teratogenicity and cytotoxcity of test compounds on differentiating mouse ESC.
*
Delivery
-A study protocol will be sent to initiate the study. Results are sent as draft and final study report.
*
*Timeline
-Experiment time: 4 weeks per compound, Draft report: within 8 weeks

ADVANTAGES µEST® EMBRYOTOXICITY SCREENING

-Early identification of compounds that are embryotoxic or teratogenic.
-Fully in-vitro system eliminates animal testing.
-Highly sensitive, only a minute amount of compound (< 50 mg) required for testing.
-Elegant technique uses GFP or SEAP as reporter.
-Time and cost-effective for a more efficient and economical use of human and financial resources.

« Show less
Mouse
Drug discovery
Development
Drug-Gene Interaction
Somatic Mutations
Germline Mutations
cardiotoxicity
drug toxicity
embryotoxicity
Developmental toxicity
embryonic
Lonza µEST
µEST screening
Lonza µEST
embryotoxicity
toxicity
embryotoxicity
Custom Cell-Based Assays
Price on request

At Axiogenesis, we welcome the opportunity and challenge to find innovative and reliable scientific solutions to client research problems so you can "use our discoveries to advance yours." Axiogenesis offers a broad range and integrated portfolio of customized contract research services including:

Assay... Show more »

At Axiogenesis, we welcome the opportunity and challenge to find innovative and reliable scientific solutions to client research problems so you can "use our discoveries to advance yours." Axiogenesis offers a broad range and integrated portfolio of customized contract research services including:

Assay development
Generation of iPSC or ESC-derived cell types
Pre-clinical and pre-market efficacy and toxicology services
Consulting services for the in-house development of stem cell technologies
Our service includes in-house testing of your compounds using our cutting-edge in vitro test systems.

We offer customizable assays that can be used for:

Drug development for cardiovascular diseases
Toxicity studies
Monitoring of cardiovascular side effects
Axiogenesis specializes in the development of in vitro iPSC- and ESC-based assays and the generation of highly purified, specialized stem cell-derived cell types (either normal or diseased). All common molecular and functional analysis techniques are utilized in formulating new assays for our clients. Axiogenesis also offers standardization services for assay systems and can provide customized types or quantities of iPSC- or ESC-derived cell lines for use in existing assay test systems. As a service to clients, Axiogenesis will customize these assay systems for research institutions and the drug, cosmetic, & chemical industries to fulfill special needs in:

Research & Development
Drug discovery & Development
Process development
Production

« Show less
Human
Mouse
Cardiovascular
neurological
Cardio
Drug discovery
neurology
CNS/Neurology
Environmental samples
neuroscience
Neuroscience
Neuropathic Pain
calming effect
Cytotoxicity
neurodegenerative disorders
neurodegenerative diseases
neuropathy
cardiovascular
biomarker
Client-specified
neurotoxcity
hERG
Nav1.5
Cav1.2
Cardiomyopathy
Neurodegenerative
cardiometabolism
Cardiac Function
Ion Channel
contractile force
cardiomyopathy
cardiotoxicity
cardiac safety
MEA
Axion Maestro
cardiotoxicity
cardiac safety
Calcium imaging
Hamamatsu FDSS
calcium efflux
calcium
Lonza µEST
embryotoxicity
toxicity
embryotoxicity
myopathy
LQT
Calcium Transients
Contractility
Impedance
Nanion CardioExcyte
Axiogenesis Cor.4CE
iPSC
Stem Cell Differentiation
Yamanaka Protocol
drug safety
Ask A Question Find what you're looking for? If not, you can ask this lab a question:

Axiogenesis has not received any ratings.

Be the first to endorse Axiogenesis

Endorse this lab